FDA issues CRL for Saphnelo SC, grants priority review to Datroway
FDA issued a complete response letter (CRL) for AstraZeneca’s Saphnelo subcutaneous formulation, indicating additional data or clarifications are required before approval. Meanwhile, the FDA granted priority review to Datroway for treatment of triple-negative breast cancer, expediting its potential market launch under a shortened review period.
1. Q4 Earnings Estimates Beyond Revenue and EPS
Analysts project AstraZeneca’s revenue growth to moderate to mid-single digits in Q4 2025, supported by Oncology franchise expansion and continued strength in Respiratory. Wall Street consensus anticipates core EPS of approximately $1.90, with revenue estimates near $13.5 billion. Key metrics include projected 15% year-over-year growth in Oncology sales, driven by Imfinzi in lung cancer and Lynparza in ovarian cancer, and a 10% rise in Rare Disease segment revenues. Operating margin is forecast to improve by 100 basis points sequentially, reflecting disciplined cost controls and favorable currency impacts.
2. FDA Priority Review for Datroway in TNBC
The FDA has granted AstraZeneca a Priority Review designation for Datroway in third-line treatment of triple-negative breast cancer, setting an action date in Q2 2026 under the PDUFA timetable. This follows positive Phase III data showing a 30% reduction in risk of disease progression versus standard chemotherapy. An FDA advisory committee meeting is expected, where regulators will evaluate the benefit-risk profile based on a median progression-free survival of 7.8 months. Approval could add an incremental $600 million of annual sales by 2028, according to sell-side forecasts.
3. Complete Response Letter for Saphnelo SC
AstraZeneca received a complete response letter from the FDA on its subcutaneous formulation of Saphnelo (anifrolumab) for systemic lupus erythematosus, citing deficiencies in manufacturing validation and comparative pharmacokinetic data. The company must submit additional clinical bridging studies and enhanced process validation plans. Management indicated that the timeline for resubmission will extend into late 2026, potentially delaying US rollout by at least 12 months and deferring expected peak sales of $400 million in this formulation.
4. Stock Performance Versus Broader Market
During the latest trading session, AstraZeneca underperformed the broader healthcare sector, with shares declining by over 2%. Market participants attributed the drop to investor concerns over the delayed US launch of Saphnelo SC and profit-taking ahead of the Q4 earnings release. Trading volumes were above the 30-day average, suggesting institutional repositioning. Options implied volatility rose to 28%, reflecting heightened uncertainty around upcoming regulatory catalysts and earnings results.